Relationship between COX-2 specific inhibitors and hypertension

Hypertension

Volumn 44, Issue 2, 2004, Pages 140-145

  Solomon, Daniel H ^a   Schneeweiss, Sebastian ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyclooxygenase; Drug therapy; Epidemiology; Hypertension, detection and control

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VASODILATOR AGENT;

AGE; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; HYPERTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; HYPERTENSION; LACTONES; MALE; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS; PYRAZOLES; RANDOM ALLOCATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SULFONAMIDES; SULFONES;

EID: 3543044381     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000136134.31846.83     Document Type: Article

References (21)

1. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121: 289-300.
2. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
3. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2 selective inhibitors. Am J Nephrol. 2001;21:1-15.
4. Chenevard R, Hurlimann, D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
5. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial dysfunction in salt-induced hypertension. Circulation. 2003;108:2308-2311.
6. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1747-1753.
7. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. JAMA. 2000;284: 1247-1255.
8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B. Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
9. Arthritis Advisory Committee-FDA Briefing Information, NDA 21-042/S007, Vioxx (Rofecoxib). FDA Medical Officer's Cardiovascular Review; 22-23. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. Accessed March 4, 2003.
10. Whelton A, White WB, Bello AE, Puma JA, Fort JG for the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
11. Romano R, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079.
12. Palmieri V, de Simone G, Arnett DK, Bella JN, Kitzman DW, Oberman A, Hopkins PN, Province MA, Devereux RB. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance. Am J Cardiol. 2001;88:1163-1168.
13. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000;160: 481-490.
14. Kington RS, Smith JP. Socioeconomic status and racial and ethnic differences in functional status associated with chronic diseases. Am J Pub Health. 1997;87:805-810.
15. Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financing Review. 1994;15:153-163.
16. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Assessment of bias by unmeasured confounders in pharmacoepidemiologic claims data studies using external data. Epidemiology. In press.
17. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
18. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen WF. Delayed nephrologist referral and inadequate vascular access in patients with advanced kidney failure. J Clin Epidemiol. 2002;55: 711-716.
19. Whelton A, Fort JG, Puma JA, Normandin D, Bellow AE, Verbrug KM, for the Success VI Study Group. Cyclooxygenase-2-specific inihibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therapeutics. 2001;8:85-95.
20. Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol. 1999;94:1393-1396.
21. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.